Afala (Afala)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsplozenges
Composition:

Active components:

Antibodies to the prostate-specific antigen are affinity purified - 0.003 g *.

Excipients: lactose monohydrate (lactose) 0.267 g, microcrystalline cellulose 0.03 g, magnesium stearate 0.003 g

* are applied to lactose in the form of a water-alcohol mixture with a content of not more than 10-15 ng / g of the active form of the active ingredient.

Description:Tablets are flat-cylindrical, with a risk and chamfer, from white to almost white. On the flat side, the inscription MATERIA MEDICA is marked with a risk, AFALA is inscribed on the other flat side.
Pharmacotherapeutic group:Prostate hyperplasia is a benign treatment tool
ATX: & nbsp
  • Other drugs for the treatment of urological diseases
    • Pharmacodynamics:Reduces the phenomenon of inflammation and swelling in the prostate gland, normalizes its functional state. Improves urodynamics, reduces the volume of residual urine, normalizes the tone of the lower sections of the urinary tract, helps reduce dysuric disorders.
    Pharmacokinetics:The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to estimate the content of ultra-small doses of antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of Afal.
    Indications:

    Benign prostatic hyperplasia of the first and second stages.

    In the complex therapy of acute and chronic prostatitis - as an anti-inflammatory and analgesic.

    Dysuric disorders (frequent urination, including nocturnal, difficulty urinating, pain or discomfort in the perineal region), including those accompanying benign prostatic hyperplasia of stage I and II; acute hronic prostatitis.

    Contraindications:Increased individual sensitivity to the components of the drug. It is not recommended for use in patients under the age of 18 due to inadequate data on efficacy and safety for this age.
    Pregnancy and lactation:The drug Afala is not intended for use in women.
    Dosing and Administration:

    Inside. At one time, 2 tablets (keep in your mouth until completely dissolved - not during meals). The drug should be taken twice a day, in the evening and in the morning (before and after sleep). The recommended duration of the drug is 16 weeks.

    With severe pain syndrome and dysuric disorders in the first 2-3 weeks of therapy, the drug is taken up to 4 times a day.

    If necessary, on the recommendation of a doctor, a repeat course of treatment can be performed after 1-4 months.

    Side effects:Possible reactions of increased individual sensitivity to the components of the drug.
    Overdose:In case of an accidental overdose, dyspepsia is possible due to the excipients included in the formulation.
    Interaction:There have been no incidents of incompatibility with other drugs to date.
    Special instructions:The composition of the drug includes lactose monohydrate, and therefore it is not recommended for patients with congenital galactosemia, glucose malabsorption syndrome or galactose, or with congenital lactase insufficiency.
    Effect on the ability to drive transp. cf. and fur:Afala does not affect the ability to drive vehicles and other potentially dangerous mechanisms.
    Form release / dosage:Lozenges.
    Packaging:

    For 20 tablets in a planar cell packaging made of polyvinylchloride film and aluminum foil.

    For 1, 2 or 5 contour mesh packages together with the instruction for medical use are placed in a pack of cardboard.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    During the period of application of the preparation, store the contour mesh package in a cardboard bundle provided by the manufacturer.

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N000371 / 01
    Date of registration:21.06.2010 / 10.08.2010
    Expiration Date:Unlimited
    The owner of the registration certificate:NPF Materia Medica Holding, OOO NPF Materia Medica Holding, OOO Russia
    Manufacturer: & nbsp
    Information update date: & nbsp20.09.2017
    Illustrated instructions
      Instructions
      Up